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Accepted 16 July 2020Differential presence of exons (DPE) is a method of interpretation of exome sequencing, which has been proposed to
design a predictive algorithm with clinical value in patients with colorectal cancer (CRC). The goal of the present
study was to examine the reproducibility in a rat model of metastatic colon cancer. DHD/K12-TRb cells were injected
in syngenic immunocompetent BD-IX rats. Cells were from two stocks with low and normal metastatic potential, and
injected into two separate groups of rats. Five to ten weeks after injection, blood samples were taken prior euthanasia
and whole exome sequencing performed. Through DPE analysis, we identified a set of exons whose differential pres-
ence in plasma allowed us to compare both groups of tumor-bearing animals. A verification test was performed to con-
firm that the algorithm was able to classify extracted samples into their corresponding groups of origin. The highest
mean probability was 0.8954. In conclusion, the DPE analysis in tumor-bearing animals was able to discriminate be-
tween different disease status, which fully supports previous results in CRC patients.Introduction
The use of liquid biopsy in the management of cancer disease has been
one of the most encouraging expectative in the last two decades. It is very
probable that analysis on liquid biopsy will not replace tumor biopsies,
however, they can provide additional insight into important clinically rele-
vant information, and there is a real need for clinically relevant and repro-
ducible targets. Notwithstanding tumor cells have been the focus of a high
number of studies on liquid biopsy, the genetic profiling of cell-free DNA
(cfDNA) in the blood is the main target of liquid biopsy [1].
Levels of cfDNA in plasma have been repeatedly examined in cancer pa-
tients [2] and tumor-bearing animals [3] and, in spite of heterogeneous re-
sults among studies, most of them have shown a link between cancer
progression and releasing of cfDNA into the blood. Discrepancies among re-
sults from different studies are mainly regarding the correlation of such
DNA with tumor stage, location, size or response to therapy. The kind of
nucleic acid and the specific sequence used as the detection target, as well
as the methods applied, are probably the main reasons for such disparity.Therapies Laboratory, Foundation He
).
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vier Inc. on behalf of Neoplasia PIn the last decade, the use of next-generation sequencing (NGS) and so-
phisticated bioinformatics analysis, have opened new possibilities to in-
crease the potential utility of cfDNA as clinical tools for diagnosis,
prognosis andmanagement of cancer patients, pointing to a precise and per-
sonalizedmedicine.Whole genome sequencing (WGS) or exome sequencing
(WES) of tumor cells and plasma cfDNA using NGS is, theoretically, an un-
biased approach that might provide extensive and comprehensive genomic
information about cancer, through the detection of mutations (SNPs) and
some structural alterations, such as indels or copy number aberrations [4].
To date, the most explored approaches using NGS have been the detec-
tion of cancer-specificmutations, and the discovering of themwithout prior
knowledge of the tumor mutation landscape [5]. However, detection of
cancer-specific mutations by NGS has not yet achieved the high sensitivity
obtained by qPCR and ddPCR [3,6] which, in addition, have a substantially
lower cost. The scope for error in NGS is problematic in rare mutation de-
tection, due to the relatively high sequencing error rate or PCR errors intro-
duced during library construction [1]. It is important to keep in mind that
the sensitivity is highly relevant in the context of liquid biopsies, in whichalth Research Institute-Fundación Jiménez Díaz University Hospital (FIIS-FJD), Avda. Reyes
ress, Inc. This is an open access article under the CC BY-NC-ND license (http://
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non-mutated molecules.
Numerous factors can impact the accuracy, sensitivity and specific-
ity of cfDNA sequencing by NGS: the sample preparation, the target
enrichment library construction, the sequencing platform, and the
bioinformatics tools. In fact, a side-by-side comparison study showed
how different may be the results of NGS of cfDNA obtained from the
same patients in different laboratories, as reviewed by Posey et al.
[7]. In summary, despite the potential utilities of NGS in cfDNA, its in-
herent limitations should not be overlooked.
Currently, many groups are designing approaches to circumvent
such limitations, and get the maximum value of NGS to detect cancer-
specific mutations, as reviewed by Kastrisiou et al. [8]. However, it is
probably necessary to open the mind to other type of approaches for
getting the maximum value of the broad information resulting from
NGS techniques.
Our group has launched a method of interpretation of exome sequenc-
ing, based on a general overview of cfDNA in plasma, which allows to per-
form it at a shallower depth and, more interestingly, allowed us to design a
predictive algorithm with clinical value in patients with colorectal cancer
[9]. Thismethodwas based on the discovery that patientswith andwithout
metastasis have a different content of exons in their plasmas, which led to a
new concept named as “differential presence of exons” (DPE) [9].
The goal of the present studywas to examine the reproducibility and the
utility of DPE approach in an animal model of metastatic colorectal cancer,
with syngenic immunocompetent rats. By this way to validate the DPE pro-
posal, we could avoid the heterogeneity and the possible bias related to any
study of a human group.
Materials and methods
Cell culture
DHD/K12-PROb cells were used (rat colon cancer cells; also called
DHD/K12-TRb cells; European Collection of Cell Cultures - ECACC no.
90062901, referred to as DHD cells herein) as malignant cells, which
were purchased to the ECACC (Salisbury, UK). Cells were cultured inmono-
layer in a mixture of DMEM and Ham's F10 (1:1, v/v; Gibco-BRL, Life Tech-
nologies Ltd., Paisley, Scotland), supplemented with 10% fetal bovine
serum (Gibco-BRL) and gentamycin (0.005%; Gibco-BRL). Cells were pas-
saged after dispersion in 0.125% trypsin in EDTA.
We used two cell populations: the first (named herein as “Old DHD”)
was continuously cultured in a steadily manner (two passes per week) for
more than 5 years. In prior own assays, we detected that when those old
DHD cells were injected in rats, metastases were slower developed than
the usual and previously standardized way [3]. The last cell population
(named as “NewDHD”) was bought and subjected to nomore than 5 passes
before being used for this study.
Animals
Both male and female BD-IX rats were used, from 6 to 7 weeks of age.
They were taken from a colony established at the authors' animal facility
from founders purchased from a commercial breeder (Charles River, Barce-
lona, Spain). The entire study was approved by the Ethics Committee for
Animal Research of Castilla-La Mancha University (Spain; code number:
2013-0705). All animals were housed and handled according to the ap-
proved protocols, under supervision by the staff of the animal facility of
the University General Hospital of Albacete. The studies were conducted
in accordance with European and Spanish laws (Directive 2010/63/UE
and Real Decreto 53/2013, respectively). As recommended by the Federa-
tion of European Laboratory Animal Science Associations (FELASA), mice
in the animal facility were tested periodically to ensure that the colony
remained free of pathogens. From birth to the end of the experiments, all
rats had unlimited access to water and standard rat chow (Teklad Lab Ani-
mal Diets; Harlan Laboratories, Barcelona, Spain).2
Implantation of tumors and design of experiments
Tumors were generated in the thoracic region by unilateral subcutane-
ous injection of DHD cells into the right side of the chest. One day before
implantation, cells were trypsinized and seeded in new flasks at a medium
confluence (30–40%), so that at the next day, cells were in the exponential-
growth phase at implantation. Immediately before cell injection in animals,
cells were trypsinized, washed, and resuspended in phosphate-buffered sa-
line (PBS). Then, 0.25 ml of this suspension, containing 1 × 106 cells, was
injected per rat.
All DHD cells were manipulated and injected in animals in a similar
way, and two animal groups were established, according to the kind of
injected cells: Group O (n = 7), injected with “Old-DHD cells” and eu-
thanized when an endpoint criterium was reached; and Group N (n =
7), injected with “New-DHD cells” (Fig. 1). This last group was divided
into two subgroups, according to the moment of the euthanasia: Sub-
group N1 (n= 4): euthanized when an endpoint criterium was reached;
Subgroup N2 (n = 3): euthanized earlier, at 5–6 weeks after cells inoc-
ulation. Each group was composed of male and female animals in simi-
lar proportions.
Animals were inspected daily by the veterinarian of the animal facility.
The body weight and the growth of subcutaneous tumors were monitored
and recorded weekly. The greatest diameter of each tumor was measured
with electronic calipers. Our previous experience with this model demon-
strated that higher-frequency analysis is unnecessary [3]. The protocol for
handling of tumor-bearing animals was designed according to recommen-
dations for ethical cancer research [10].
Axillary lymphnodes and lungswere inspected visually for the presence
or absence of metastases, which was recorded.
Animals were euthanized when reached at least one of the follow-
ing endpoint criteria: (i) greatest diameter of primary tumor higher
than 4 cm; (ii) ulceration of primary tumor; or (iii) weight loss higher
than 10%.
Collection of blood samples
At the moment of the euthanasia, rats were anesthetized with an intra-
peritoneal injection of a mixture of ketamine (75 mg/kg) and xylazin
(10 mg/kg). Then blood (approximately 4.0 to 4.5 ml per rat) was with-
drawn by cardiac puncture and a lethal dose of sodium thiopental was ad-
ministered intracardially immediately afterwards. All blood samples were
collected in tubes with EDTA and subjected to centrifugation (1800 ×g,
10 min, 4 °C). Plasma was collected and subjected to a second centrifuga-
tion at 3000×g for 10 min. The plasma samples were aliquoted and stored
at−80 °C prior to extraction of DNA.
Extraction of cfDNA from plasma samples
DNA was extracted from 1-ml samples of plasma with a commercial kit
(QIAamp Circulating Nucleic Acid Kit; QIAGEN GmbH, Hilden, Germany)
according to the instructions from the manufacturer. DNA samples were
then stored at −20 °C.
Library preparation, exome-capture, and sequencing
Concentration, quantity, and integrity of cfDNAwere estimated prior to
use. The size distribution of cfDNA fragments was determined using a 2100
BioAnalyzer (Agilent Technologies, Santa Clara, CA, USA). Library prepara-
tion and specific exome capture were performed using a custom EZ-
Developer capture system prepared according to the coordinates of the
complete rat exome (Roche NimbleGen, Basel, Switzerland). Libraries
were hybrid-captured using biotinylated probes. Adapter DNA sequences
were placed on both ends, and exomes were sequenced on the Illumina
NextSeq500 platform (Illumina, Inc., San Diego, CA, USA) with 75 bp
paired-end reads. Library preps and sequencing were performed at the Ge-
nomic Facility of the Scientific Park of Madrid, Spain.
Fig. 1. Schematic representation of the experimental design. Two sublines of DHD cells were injected in BD-IX rats, which were classified into two groups: group O, injected
with the named “old cells”, with low-metastatic potential; and group N, injected with the named “new cells”, with normal-metastatic potential. When animals met the
endpoint criteria, blood samples were taken and plasma cfDNA samples were subjected to whole exome sequencing. Then, bioinformatics analyses were performed.
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Fourteen samples were sequenced (7 from each group of tumor-bearing
animals), obtaining a total of around 543 M of 2 × 76 nt reads. The read
depth varied in a range from 59× to 104×, with an average read depth
of 82× per sample. Reads quality analyses were performed using the
FastQC software (Brabaham Bioinformatics) [11]. Reads were aligned
against the Rattus norvegicus genome (6.0.88) using Bowtie aligner [12]
allowing up to 3 mismatches (parameters: -v 3 -k 1 –best).
Detection of differentially present exons (DPE)
Sequencing data were processed as in a standard RNA-seq analysis, but
trying to highlight DPE rather than differentially expressed genes. This
analysis was done with ‘EdgeR’ R package [13]. Reads counts by exon
were calculated with HTSeq-count [14]. Edger's background statistical
methods were based on generalized linear models (glm), which test for
DPE using either likelihood ratio tests (LRT) [13] or quasi-likelihood F-
tests (QLF) [15]. The DPE for a threshold p-value of p≤ 0.005was selected,
and MA plots for such DPE were drawn.
DPE clustering and principal components analysis (PCA)
Normalized DPE counts (counts per million, CPM) were calculated for
every exon for each sample using EdgeR. These counts were used to cluster
the samples using Ward's method [16], to verify that all samples were be-
having properly. Additionally, principal components analysis (PCA) was
performed with an in-house R script.
Random Forest (RF) classification
Random Forest (RF) classification was implemented with an in-house R
script using the ‘randomForest’ package [17]. Two samples from both O
and N groups were randomly selected and extracted, using the five remain-
ing samples of each group (10 samples in total) as a ‘training set’ to generate
a predictive algorithm. One hundred classifications were performed by iter-
ation of this process, calculating the mean value of the obtained probabili-
ties. The accuracy of the resulting model was tested by checking its ability3
to correctly classify randomly extracted samples into their corresponding
groups of origin.
Pathway analysis
Data were analyzed with Ingenuity Pathway Analysis (IPA®, Qiagen,
http://www.qiagenbioinformatics.com; [18]), a software application for
the analysis and interpretation of data derived from omics experiments.
The list of over-represented genes for each group were imported into IPA
and mapped to the IPA Knowledge Database. We performed the Core Anal-
ysis for predicting pathways and molecular functions affected, based on
gene expression. The significance of the association between the dataset
and the specific pathways was determined by Right Tailed Fisher's Exact
Test (p< 0.05). AWilcoxon–Mann–Whitney test was performed for paired
samples to analyze whether the percentage of genes from both groups were
differentially distributed in the main function categories.
Statistical analysis
For variables related to the clinical course of tumors in the animals,
comparisons of means were made by Student's t-test for normal distribu-
tions and by the Kruskal-Wallis tests for non-normal distributions. A p-
value of less than 0.05 was accepted as evidence of statistical significance.
Qualitative variables were compared using the χ2 test and Fisher's exact
test when any frequency was less than 5. Two-tailed p-values of less than
0.05 were considered evidence of statistical significance. Such statistical
analyses were performed with StatPlus, version 2009 (AnalystSoft) and
OpenEpi (Open Source Epidemiologic Statistics for Public Health, Version
2.3.1, www.OpenEpi.com).
Right Tailed Fisher's Exact Test was used for IPAwith a cutoff p-value of
p< 0.05. AWilcoxon–Mann–Whitney test for paired samples was also per-
formed for gene distribution in IPA main function categories. LRT and QLF
tests were performed for DPE with a p-value of p ≤ 0.005.
Data availability
Whole-exome sequencing data that supports the findings of this study
has been deposited in the European Nucleotide Archive (ENA) with the ac-
cession number PRJEB37894.
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Results
Body weight and growth of tumors
In the two groups, the mean of body weight was increasing along the
experiment, except in the last two weeks tested in the Group N (Fig. 2A).
The initial body weight ranged from 112 g to 154 g, and the final weight
(at euthanasia), from 205 to 395 g. There was no statistically significant
difference between the two groups. As expected, the mean body weight
of male animals (n = 7) was higher than that of female ones (n = 7;
Fig. 2B), with statistically significant differences, at all weeks except
for the moment of cells injection.
Tumors were detectable in rats from the first week after inoculation of
DHD cells and grew at an apparently uniform rate for the duration of the ex-
periment (Fig. 3A). The means of the tumor diameters were similar among
groups at all weeks. However, there was statistically significant difference
betweenmale and female rats at all weeks, except for the first one (Fig. 3B).
Macroscopic observations
Lung macrometastases were not detected in animals in group O and in
subgroup N2. However, such metastases were macroscopically visible inFig. 2. Rats growth during the study. Values shown are mean body weight (±SD). A. S
normal metastatic potential, respectively). B. Separate curves for female and male anim
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all rats in subgroup N1 There was no difference between male and female
animals.
cfDNA isolation from plasma and NGS
Circulating cfDNA was successfully extracted from all plasma
samples, obtaining disparate concentrations of DNA ranging from
0.02 to 97.35 ng/μL. There was not statistically significant difference
between groups.
BioAnalyzer plots revealed a cfDNA size > 1 kb. All samples were sub-
jected to a mechanical fragmentation process using Bioruptor® Sonication
System (Diagenode, Liège, Belgium) to obtain fragments with a length of
around 145 bp. Adapter DNA sequences were placed yielding a total length
of 170 bp.
The total number of reads per sample ranged from 33 to 45 million.
Quality analyses of reads using the FastQC software (Phred+33 quality
score) revealed that more than 85% of the bases had a >Q30 quality. The
Supplementary Table 1 shows the total number of reads, depth of exome
coverage, GC content, and percentage of aligned and unaligned reads of
each sample.
DPE analysis
We identified a set of exons whose differential presence in plasma
allowed us to compare group O vs group N1 and group N2. There was no
difference between male and female animals. DPE was analyzed witheparate curves for animals injected with “Old” and “New” DHD cells (with low and
als.
Fig. 3.Tumor growth in rats after subcutaneous injection of DHD cells. Values shown aremeanmaximum diameters of tumors (±SD). A. Separate curves for animals injected
with “Old” and “New” DHD cells (with low and normal metastatic potential, respectively). B. Separate curves for female and male animals.
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≤0.005 for each comparison. For O vs N1 comparison, a total of 102 and
244 exons were obtained respectively, yielding 258 exons overall, includ-
ing unique and common exons. For O vs N2 comparison, a total of 331
and 783 exons were obtained, yielding 793 unique and common exons. A
total amount of 1028 differentially present exons were found, considering
both comparisons and methods.
MA plots for both comparisons and methods are showed in Fig. 4, in
which the exons identified as DPEs in each comparison are in red. Those
statistically significant exons were located on the margins of the point
cloud, as expected.
Then, we examined in which genes were located those exons. Consider-
ing that some exons belong to the same gene, finally we identified a total of
937 genes, of which 447 were over-represented in group N1, and 481 in
group O (for O vs N1 comparison), and 413 were over-represented in
group N2, and 521 in group O (for O vs N2 comparison; Supplementary Ta-
bles 2 and 3).
DPE clustering
Clustering of normalized DPE was performed byWard's method, which
gives a distances tree shown in Fig. 5. Samples were properly clustered,
maintaining the separation between the O, N1 and N2 samples. Next,
PCAs were performed and Fig. 6 shows a bidimensional plot with the first
two principal components. As can be seen, groups O, N1 and N2 are clearly
separated and clustered properly.5
These results encouraged us to develop a predictive algorithm to classify
samples. To achieve this goal, a RF classification was obtained after 100 it-
erations (Fig. 7), extracting two randomly selected samples from each
group (O and N), and generating a predictive model, with the 10 remaining
samples (five per group) as a training set. A verification test was performed
to confirm that the algorithm was able to classify extracted samples into
their corresponding groups of origin, by calculating the average probabili-
ties of belonging to one group or another (Supplementary Table 4). The ex-
tracted samples were correctly identified, with a mean value of p= 0.7268
with a standard deviation of S= 0.1167, and the highest mean probability
was p_max = 0.8954.
We also made an alternative approach, extracting three samples from
both O and N groups and using the four remaining samples of each group
(8 samples in total) as a ‘training set’. Such approach had not significantly
improved the prediction; specifically, we obtained a value of p = 0.7111
with a standard deviation of S= 0.1277, and the highest mean probability
was p_max = 0.9006 (Supplementary Fig. 1).
Pathway analysis
We performed a pathway analysis using IPA to gain further insight into
the functional annotation of the 937 over-represented genes. Such analysis
that showed that over-represented genes in groups O and N2 were related
to three major biological functions: ‘mitochondrial dysfunction’, ‘oxidative
phosphorylation’, and ‘sirtuin signaling pathway’, while genes that were
over-represented in group N1 were related to major biological functions
Fig. 4.MAplots for selected differentially present exons combining two differentmethods: Likelihood Ratio Tests (LRT) andQuasi-Likelihood F-tests (QLF) and two different
comparatives (group O vs groupN1, and group O vs group N2). The log ratio of fold-change (FC) is plotted on the y-axis, and the average of the normalized counts (counts per
million; CPM) is plotted on the x-axis. Differentially-present exons are highlighted in red (DPEs; p≤ 0.005). A. LRT method for the comparison of group O vs group N1 (244
DPEs). B. QLF method for the comparison of group O vs group N1 (102 DPEs). C. LRT method for the comparison of group O vs group N2 (783 DPEs). D. QLFmethod for the
comparison of group O vs group N2 (331 DPEs).
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8, and Supplementary Figs. 2 to 5). Regarding networks, for O vs N1 com-
parison, over-represented genes in group N1 were associated to 12 net-
works whereas those in group O were related to other 25 different
networks, and for O vs N2 comparison, over-represented genes in group
N2 were associated to 13 networks whereas those in group O were related
to 25 networks (Supplementary Tables 9 to 12).
Discussion
The use of NGS-based techniques in blood has opened a wide field for
exploring new precise - even personalized- biomarkers, with potential clin-
ical utility in cancer. In fact, in the last decade, there have beenmany efforts
to explore this sophisticated tool, and to generate accurate and feasible
techniques for the management of the cancer disease [1,8]. However, we6
should not overlook that information resulting from NGS might be valu-
able, not only for clinical use, but also to deepen in the high-complexmech-
anism of the cancer progression.
Using NGS-based techniques in tumors, Gerlinger et al. [20] got strong
evidences of the intratumor heterogeneity (ITH), suggesting that such phe-
nomenon might lead to underestimation of the tumor genomics landscape
and might present major challenges to personalized-medicine and bio-
marker development. With respect to colorectal cancer (CRC), the idea of
clonality - lengthily assumed after the establishment of the multi-step carci-
nogenesis model [21] - has recently been revised by a series of studies dem-
onstrating IHT in advanced cancer, as well as in precancerous lesions
[22,23]. Specifically, it has been suggested that ITH is an inherent charac-
teristic of colorectal tumors that arises early and continuously increases
during growth, and is not significantly constrained by clonal selection
[22]. Such heterogeneity might affect the possibility to reliably identify
Fig. 5. Clustering of samples using normalized values of differentially present exons (DPEs). A. Heatmap representation of the presence levels of DPEs. Presence levels are
shown on a log2(CPM + 1) scale to avoid possible null values, covering a range from 3 (yellow, highest level) to−3 (cyan, lowest level). Color bars at the top of the plot
indicate experimental group of the samples. B. Clustering of samples by Ward's Method. Animals were individually named as BL-number and, in this figure, are marked
by different colors according to the group in which were included: O: green, N1: red; and N2: blue.
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ever, since plasma receives DNA from the various heterogeneous
tumor clones in the body, sequencing of plasma DNA from a different
point of view than mutational status, might be a readily available and
noninvasive method for studying and monitoring tumoral heterogeneity
and progression.
For this reason, the technologically-advanced approaches focused on
the overview of cfDNA circulating in plasmamight result in a deeper under-
standing of cfDNA biology -which is essential for the practical application ofFig. 6. Bidimensional principal components analysis (PCA) plot. Group O, N1 and
N2 samples are marked by different colors: O: green, N1: red; and N2: blue.
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liquid biopsy-, and even in useful and reproducible tools for clinical man-
agement. In this sense, through WES techniques, we have previously
shown that a series of CRC patients with and without metastasis have a dif-
ferent content of exons (DPE) in their plasmas [9]. Such DPE profiles led to
a DPE algorithm that was capable of providing a predictive model, by
which, metastatic and non-metastatic patients were correctly clustered
and clearly separated [9].
In the current study, we have fully corroborated the predictive value of
the DPE algorithm in a rat model of CRC, in a very-similar way. We have
used a well-known rat model of metastatic CRC, which have been repeat-
edly used by our group [3,25–28]. We have reported that lung metastases
are macroscopically found between the 8th and the 11th week after injec-
tion of tumor cells, regardless the site of injection [27,28]. In the current
study, the model had a special feature, because we used a cell subline
which had spontaneously hampered the development of metastases when
was injected in rats. We took advantage of this change to compare rats
with the usual metastatic tumors (grouped herein in group N) and rats
with the hampered disease (group O). Animals in group N that were eutha-
nized when reached ethical endpoint criteria (subgroup N1), had lung
macro metastases, whereas such metastases were not found in any animal
in the group O.
By the DPE algorithm, those two groups were purely distinguished,
in a similar way that previously reported in CRC patients [9], although
the absolute values of the analyses were different, as expected in a dif-
ferent species. In the DPE analysis of plasma of CRC human patients, we
found a lesser number of differentially-present exons than in rats (379
exons vs 1028, respectively). However, in the two species the algo-
rithm was able to classify extracted samples into their corresponding
groups of origin, by calculating the average probabilities of belonging
to one of the groups. In tumor-bearing rats, the highest mean probabil-
ity to correctly classify a sample was higher than in CRC patients
(0.8954 vs 0.68).
In addition, we established a subgroup in group N (subgroup N2) in
which rats were early euthanized when lung metastases were not macro-
scopically detected. Clustering of normalized DPE by Ward's method gave
Fig. 7. Kernel Density Estimation (KDE) of the distribution of probabilities obtained from 100 iterations of a Random Forest (RF) classification. In each iteration, two
randomly selected samples from each group (O and N, joining N1 and N2 groups), were extracted and classified with a predictive RF model using the 10 remaining
samples (five per group) as a training set. A. KDE distribution of the probabilities of being metastatic. B. KDE distribution of the probabilities of being correctly assigned
to the corresponding group of origin. Group O is marked in green and Group N in red.
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separation between the O, N2 andN1 samples. Probably, if N2 ratswere eu-
thanized later, with metastases, samples would have been clustered in the
N1 area. These results suggest that the DPE profile is dynamic and change
with the cancer progression in a similar way among animals.
The functional analysis of the over-represented exons in each group did
not lead to any conclusion about the reason of such abundance and its con-
nection of cancer progression, if any. Nonetheless, the fact is that a differen-
tial detection of exons was able to distinguish between tumor-bearing
animals with different tumor status,which lead to hypothesize that changes
in molecular behavior of tumors are more extensive and intensive than be-
lieved, and might be monitored by a DPE analysis.
In addition, the fact that certain exons were more represented than
others, and that such profiles were repeated among animals in the same
group, support the idea of an active and intelligent release of nucleic
acids by cells. Historically, the most-persistent theory about the origin of
cfDNA has been the cell death [29], however, if this phenomenon were
the unique or even the predominant, the expected results would have
been a uniform releasing of exons or in a random appearance, without pre-
dominance of none.
The active and intelligent releasing of cfDNA links with the theory that
such phenomenon is not a waste phenomenon, but a step of a putative path-
way for tumor progression [30]. Horizontal transfer of such cfDNA between
cells has been proposed as a pivotal mechanism in the development of me-
tastasis both in vitro and in vivo, a phenomenon called genometastasis
[30,31], which has been proved in mixed in vivo and in vitro models
[32,33]. Thus, under this view, the cfDNA found in plasma of animals
and patientsmight have been, to a greater or lesser extent, actively secreted
by both tumor and non-tumor cells, and may contribute to metastasis.
Summarizing, the DPE analysis in tumor-bearing animals was able to
discriminate betweendifferent disease status,which fully supports previous
results in CRC patients. DPE analysis is affordable from WES results with a
minimal bioinformatic structure. Hence, our findings encourage to analyze
under this perspective any NGS results obtained in series of cancer patients,
to gain complementary approaches of the status of the illness. In addition,
the results found here support the theory of an active and directed releasing
of cfDNA.8
Supplementary data to this article can be found online at https://doi.
org/10.1016/j.tranon.2020.100837.
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